To determine if the prevalence of antibodies against the identified tumor-associated antigens (CTAG2, MAGEB4, SHARPIN, MAGEA12, MAGEA4, MRFAP1L1, PNMA2, AURKA, SERPINB1 and XAGE3) is reflected in the prevalence of the respective gene expression across ovarian cancer patients, we assessed a separate serous ovarian cancer cohort accessible via TCGA (n = 307/606 with available mRNA expression data) for gene expression (no gene expression data were available for BAGE4). This evidence concerns the gene AURKA and ovarian cancer.